Evidence map›Paper›PMID 40605002›Full record

ArticleGenome biology2025

Z-scores outperform similar methods for analyzing CRISPR paralog synthetic lethality screens.

Juihsuan Chou, Nazanin Esmaeili Anvar, Reem Elghaish, Junjie Chen, Traver Hart

Abstract read
In one paragraph

Article in Genome biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Juihsuan ChouDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nazanin Esmaeili AnvarDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Reem ElghaishDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Junjie ChenDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Traver HartDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. traver@hart-lab.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Exploring DNA damage response pathways as targets for cancer therapyR35CA274234 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Junjie Chen · 2022 to 2026
$4.4M
High-content microscopy platform for multiplex perturbation/multiplex readout studiesR35GM130119 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Traver Hart · 2018 to 2026
$3.9M
NCI NIH HHS P30 CA016672NCI NIH HHS P30CA16672NCI NIH HHS R35 CA274234NCI NIH HHS R35CA274234NIGMS NIH HHS R35 GM130119NIGMS NIH HHS R35GM130119
6 · The paper itself

Abstract

Genetic screens offer a promising strategy for identifying tumor-specific therapeutic targets, but single-gene knockout screens often miss functionally redundant paralogs. Multiplex Cas9 and Cas12a CRISPR systems have been deployed to assay genetic interactions, but analysis pipelines vary considerably. Here we evaluate data from four in4mer CRISPR/Cas12a screens in cancer cell lines, using delta log fold change, Z-transformed dLFC, and rescaled dLFC approaches to identify synthetic lethal interactions. Both ZdLFC and RdLFC provide more consistent identification of synthetic lethal pairs across cell lines compared to the unscaled dLFC method, while ZdLFC benefits from not requiring a training set of known interactors.

Indexed as

CRISPR-Cas SystemsSynthetic Lethal MutationsCell Line, TumorHumans

Identifiers

PMID40605002
PMCPMC12217507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.